Effects of toremifene and its main metabolites on growth of breast cancer cell lines

D. Coradini, A. Biffi, V. Cappelletti, G. Di Fronzo

Research output: Contribution to journalArticle

Abstract

The effects of toremifene, an antiestrogen, and its two main metabolites (4-hydroxy- and N-desmethyltoremifene) on cell proliferation have been tested in a series of breast cancer cell lines, with positive (MCF7, ZR 75.1, T47D, 734B) or negative steroid receptor status (MDA-MB 231, BT20). Drug effects were evaluated at concentrations similar to those obtained in breast cancer patients on toremifene treatment, and in the presence or absence of estradiol. Results showed that, for both positive and negative cell lines, high concentrations of the antiestrogens (10-6M) were inhibitory, while lower doses (10-7M, 10-8M) were stimulatory. These data confirm the biphasic behaviour of toremifene and its derivatives. In terms of a clinical application of toremifene, these results seem to suggest that while high doses of toremifene and its derivatives might be therapeutic, lower concentrations might stimulate cell growth and enhance tumor progression.

Original languageEnglish
Pages (from-to)2191-2197
Number of pages7
JournalAnticancer Research
Volume11
Issue number6
Publication statusPublished - 1991

Fingerprint

Toremifene
Breast Neoplasms
Cell Line
Growth
Estrogen Receptor Modulators
Steroid Receptors
Estradiol
Cell Proliferation
Therapeutics
Pharmaceutical Preparations
Neoplasms

Keywords

  • Antiestrogen
  • Breast cancer
  • Cell culture
  • Toremifene

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Effects of toremifene and its main metabolites on growth of breast cancer cell lines. / Coradini, D.; Biffi, A.; Cappelletti, V.; Di Fronzo, G.

In: Anticancer Research, Vol. 11, No. 6, 1991, p. 2191-2197.

Research output: Contribution to journalArticle

Coradini, D. ; Biffi, A. ; Cappelletti, V. ; Di Fronzo, G. / Effects of toremifene and its main metabolites on growth of breast cancer cell lines. In: Anticancer Research. 1991 ; Vol. 11, No. 6. pp. 2191-2197.
@article{e631c18c16264324bd6b66ba0ab7aa7f,
title = "Effects of toremifene and its main metabolites on growth of breast cancer cell lines",
abstract = "The effects of toremifene, an antiestrogen, and its two main metabolites (4-hydroxy- and N-desmethyltoremifene) on cell proliferation have been tested in a series of breast cancer cell lines, with positive (MCF7, ZR 75.1, T47D, 734B) or negative steroid receptor status (MDA-MB 231, BT20). Drug effects were evaluated at concentrations similar to those obtained in breast cancer patients on toremifene treatment, and in the presence or absence of estradiol. Results showed that, for both positive and negative cell lines, high concentrations of the antiestrogens (10-6M) were inhibitory, while lower doses (10-7M, 10-8M) were stimulatory. These data confirm the biphasic behaviour of toremifene and its derivatives. In terms of a clinical application of toremifene, these results seem to suggest that while high doses of toremifene and its derivatives might be therapeutic, lower concentrations might stimulate cell growth and enhance tumor progression.",
keywords = "Antiestrogen, Breast cancer, Cell culture, Toremifene",
author = "D. Coradini and A. Biffi and V. Cappelletti and {Di Fronzo}, G.",
year = "1991",
language = "English",
volume = "11",
pages = "2191--2197",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "6",

}

TY - JOUR

T1 - Effects of toremifene and its main metabolites on growth of breast cancer cell lines

AU - Coradini, D.

AU - Biffi, A.

AU - Cappelletti, V.

AU - Di Fronzo, G.

PY - 1991

Y1 - 1991

N2 - The effects of toremifene, an antiestrogen, and its two main metabolites (4-hydroxy- and N-desmethyltoremifene) on cell proliferation have been tested in a series of breast cancer cell lines, with positive (MCF7, ZR 75.1, T47D, 734B) or negative steroid receptor status (MDA-MB 231, BT20). Drug effects were evaluated at concentrations similar to those obtained in breast cancer patients on toremifene treatment, and in the presence or absence of estradiol. Results showed that, for both positive and negative cell lines, high concentrations of the antiestrogens (10-6M) were inhibitory, while lower doses (10-7M, 10-8M) were stimulatory. These data confirm the biphasic behaviour of toremifene and its derivatives. In terms of a clinical application of toremifene, these results seem to suggest that while high doses of toremifene and its derivatives might be therapeutic, lower concentrations might stimulate cell growth and enhance tumor progression.

AB - The effects of toremifene, an antiestrogen, and its two main metabolites (4-hydroxy- and N-desmethyltoremifene) on cell proliferation have been tested in a series of breast cancer cell lines, with positive (MCF7, ZR 75.1, T47D, 734B) or negative steroid receptor status (MDA-MB 231, BT20). Drug effects were evaluated at concentrations similar to those obtained in breast cancer patients on toremifene treatment, and in the presence or absence of estradiol. Results showed that, for both positive and negative cell lines, high concentrations of the antiestrogens (10-6M) were inhibitory, while lower doses (10-7M, 10-8M) were stimulatory. These data confirm the biphasic behaviour of toremifene and its derivatives. In terms of a clinical application of toremifene, these results seem to suggest that while high doses of toremifene and its derivatives might be therapeutic, lower concentrations might stimulate cell growth and enhance tumor progression.

KW - Antiestrogen

KW - Breast cancer

KW - Cell culture

KW - Toremifene

UR - http://www.scopus.com/inward/record.url?scp=0026342549&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026342549&partnerID=8YFLogxK

M3 - Article

C2 - 1837981

AN - SCOPUS:0026342549

VL - 11

SP - 2191

EP - 2197

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 6

ER -